Peter Hohenberger - Concepedia

Author

Peter Hohenberger

Also Known As

Audrey Helaine, Hohenberger, P., Hohenberger, Peter, J Waldschmidt, P Hohenberger, P. Hohenberger, P. Hohenberger, P., Hohenberger, Peter Hohenberger

729

Publications

33.1K

Citations

H-Index

151

Concepts

All Affiliations

Heidelberg University University Medical Centre Mannheim University Hospital Heidelberg Fondazione IRCCS Istituto Nazionale dei Tumori Centre Léon Bérard

About

Peter Hohenberger is an author at Heidelberg University specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	46	109	13.3K
2	Health Sciences	20	34	1.6K
3	Engineering	11	11	348
4	Biomedical Engineering	6	6	612
5	Allergy	1	1	52

Peter Hohenberger

218

Publications

27K

Citations

H-Index

Page 1

	Year	Citations
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up Paolo G. Casali, N. Abecassis, Sebastian Bauer, Annals of Oncology	2018	1.6K
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial George D. Demetri, Peter Reichardt, Yoon‐Koo Kang, The Lancet Gastrointestinal OncologyMedicinePharmacologyPathologyPharmacotherapy	2012	1.4K
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial Ian Judson, Jaap Verweij, Hans Gelderblom, The Lancet Oncology Metastatic Soft-tissue SarcomaVersus Intensified DoxorubicinOncologyMalignant DiseasePathology	2014	1.1K
One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, JAMA	2012	955
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours Maria Dêbiec‐Rychter, Raf Sciot, Axel Le Cesne, European Journal of Cancer OncologyGastrointestinal OncologyMedicineKit MutationsDose Selection	2006	893
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ Alessandro Gronchi, Aisha Miah, Angelo Paolo Dei Tos, Annals of Oncology Surgical OncologySoft Tissue SurgeryVisceral SarcomasSurgical PathologyHistopathology	2021	879
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial Patrick Schöffski, Sant P. Chawla, Robert G. Maki, The Lancet OncologyMetronomic TherapyPharmacologyAdvanced LiposarcomaEribulin Versus Dacarbazine	2016	753
Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up Paolo G. Casali, N. Abecassis, Sebastian Bauer, Annals of Oncology	2018	747
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study Rolf D. Issels, Lars H. Lindner, Jaap Verweij, The Lancet Oncology Surgical OncologyRegional HyperthermiaMalignant DiseaseMedicineRandomised Phase 3	2010	649
NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines George D. Demetri, Robert S. Benjamin, Charles D. Blanke, Journal of the National Comprehensive Cancer Network	2007	635

Page 1